MONTRÉAL, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Bombardier Inc. (“Bombardier”) today announced that it has successfully priced its offering of US$250 million aggregate principal amount of Senior Notes due 2033 (the “Additional Notes”). The Additional Notes will be a further issuance of, and form a single series with, the existing $500 million aggregate principal amount of its 6.750% Senior Notes due 2033 that were originally issued on May 29, 2025. The Additional Notes will carry a coupon of 6.750% per annum a ...

PresentationGood afternoon, everyone. My name is Sheila Kahyaoglu, the Jefferies Aerospace Defense and Airlines Equity Research Team. Thanks so much for being here for our last fireside chat of the day. We have Joe Adams from FTAI Aviation. Joe is going to start with a few minutes of prepared remarks, and then we'll get to Q&A.Joseph AdamsChairman, CEO & Director Thanks very much, Sheila. Appreciate being here once again. It's a great conference, and it's a great way to kick off the fall season with a lot o ...

MONTREAL, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces that it has terminated its previously disclosed rights offering and that it is proceeding with a non-brokered private placement offering of units of the Company (the “Units”) to raise maximum gross proceeds of $5,000,000 (the “Unit Offering”). Each Unit will be offered at a price of $5,000 per Unit and is comprised of 62,500 common shares in the capital of the Company (the “Common Shares”) a ...

Lululemon Athletica slashed its annual revenue and profit forecasts on Thursday, signaling a slowdown in demand going into the crucial holiday season as consumers cut down spending, alongside tariff pressures.Shares of the company fell about 14% after the closing bell.The sportswear maker has failed to spark a wave of buying from consumers grappling with inflation and the Trump administration’s volatile trade policy.Lululemon has failed to spark a wave of buying from consumers grappling with inflation and t ...

Core Insights - Torrid Holdings reported quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.04 per share, and down from $0.08 per share a year ago, representing an earnings surprise of -50.00% [1] - The company posted revenues of $262.81 million for the quarter ended July 2025, surpassing the Zacks Consensus Estimate by 1.24%, but down from $284.64 million year-over-year [2] - Torrid Holdings shares have declined approximately 54.9% year-to-date, contrasting with the S&P 500's gain of 9.6% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.03 on revenues of $255.37 million, and for the current fiscal year, it is $0.14 on revenues of $1.04 billion [7] - The estimate revisions trend for Torrid Holdings was favorable prior to the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Retail - Apparel and Shoes industry, to which Torrid Holdings belongs, is currently ranked in the bottom 39% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Another company in the same industry, Stitch Fix, is expected to report a quarterly loss of $0.13 per share, reflecting a year-over-year change of -8.3%, with revenues projected at $301.33 million, down 5.7% from the previous year [9]

Core Insights - The new CEO of OUTFRONT, Nicolas Brien, has a background primarily in the media marketing industry, specifically on the agency side, indicating a shift to the supply side of the business [2] - Brien has been a board member of OUTFRONT for 10 years and took over as Interim CEO on February 7, suggesting a long-term commitment to the company [3] Company Background - OUTFRONT has potential in the out-of-home medium that has not been fully optimized, which may be due to marketing positioning and sales strategies [2] - The transition of Brien from an agency role to a CEO role reflects a strategic change in leadership aimed at enhancing the company's market approach [2][3]

Core Viewpoint - Bombardier Inc. has announced a conditional redemption of its outstanding Senior Notes, indicating a strategic move to manage its debt obligations effectively [1]. Group 1: Redemption Details - Bombardier issued a conditional notice of redemption for all of its outstanding 7.125% Senior Notes due 2026, with a redemption date set for October 4, 2025 [1]. - A conditional notice of partial redemption for US$83,711,000 of its 7.875% Senior Notes due 2027 has also been issued, with the same redemption date of October 4, 2025 [1]. - The redemption price for both the 2026 and 2027 Notes will be 100% of the principal amount redeemed, plus accrued and unpaid interest [1]. Group 2: Conditions and Payment Process - The redemption of the Notes is contingent upon Bombardier completing a new offering of debt securities totaling at least US$250 million before the redemption dates [1]. - Payment for the redemption will be processed through the Depository Trust Company on October 6, 2025 [2]. - The paying agent for this transaction is Deutsche Bank Trust Company Americas, located in Jacksonville, Florida [2].

Core Insights - Faraday Future Intelligent Electric Inc. will host its 919 Futurist Day & Shareholders' Day on September 19, 2025, at its headquarters in Los Angeles [1] - The event aims to enhance transparency, stockholder engagement, and long-term value creation as the company advances its dual flywheel strategy [2] Company Overview - Faraday Future is a California-based global shared intelligent electric mobility ecosystem company, founded in 2014, with a mission to disrupt the automotive industry through a user-centric and technology-first approach [3] - The flagship model, FF91, represents the company's vision for luxury, innovation, and performance, while the new FX strategy focuses on introducing mass production models targeting a broader market with middle-to-low price range offerings [3] Event Highlights - The event will feature exclusive insights into the FX Super One's product features and the Middle East launch and delivery plan [4] - Milestones from national co-creation and sales events will be shared, along with announcements of new partners [4] - The company will release details regarding the C10 & Crypto strategic business plan and roadmap for capital value realization [4]

Core Insights - Faraday Future Intelligent Electric Inc. will host its 919 Futurist Day & Shareholders' Day on September 19, 2025, at its headquarters in Los Angeles, emphasizing transparency and stockholder engagement [1][10] - The event will showcase the company's dual flywheel strategy, including the EAI Flywheel and Crypto Flywheel, aimed at long-term value creation [2] Company Overview - Faraday Future is a California-based company founded in 2014, focused on creating a user-centric, technology-first smart driving experience [3] - The flagship model, FF91, represents the company's vision for luxury and innovation, while the new FX strategy aims to introduce mass production models targeting a broader market with middle-to-low price range offerings [3] Event Highlights - The 919 Futurist Day will include an exclusive immersive experience of FX Super One's product features and insights into the FX Super One's Middle East launch and delivery plan [6] - The event will also cover milestones from national co-creation and sales events, announce new partners, and provide a strategic review of the FX brand's first anniversary [6] - Additional announcements will include details on the C10 & Crypto strategic business plan and the product deployment strategy for the FF EAI Ecosystem Vehicle Chain [6]

Company Overview - SeaStar Medical Holding Corporation is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life [3] - The company's first commercial product, QUELIMMUNE, is based on its patented Selective Cytopheretic Device (SCD) technology and was approved by the FDA in 2024 [3] - QUELIMMUNE is the only FDA-approved product for the ultra-rare condition of life-threatening acute kidney injury (AKI) due to sepsis in critically ill pediatric patients [3] Product and Technology - The Selective Cytopheretic Device (SCD) therapy has received Breakthrough Device Designation for six therapeutic indications from the FDA, which may facilitate a faster approval process and better reimbursement dynamics [3] - SeaStar Medical is currently conducting a pivotal trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy (CRRT), a condition affecting over 200,000 adults in the US annually [3] Upcoming Events - SeaStar Medical will participate in the HC Wainwright 27th Annual Global Investment Conference, with a presentation scheduled for September 5, 2025, at 7:00 am Eastern Time [1][2]